Abstract
Background: As countries and industries continue to cope with the unparalleled challenges presented by the novel coronavirus (COVID-19), a specific area of concern has been the uncertainty surrounding the impact of the COVID-19 pandemic on the global and Indian supply chains of the pharmaceutical industry. The COVID-19 crisis has demonstrated the importance of establishing a risk management system that focuses on assessing future risks resulting from the loss of a supply chain among countries.
Objective: This review focuses on the role of the Indian pharmaceutical industry towards the pandemic. This review investigates the economic effect of COVID-19 across segments and what it implies for the Indian economy.
Methods: The COVID 19 flare-up has additionally commenced the Indian pharmaceutical organizations an opportunity to transform into a supported trade place point for gathering drugs and intermediates.
Results: An enormous pharmaceutical industry in India has consistently been a foundation of reasonable human services, and this pattern would now be able to be required to heighten further.
Conclusion: The activities from COVID-19 are with a need to change the overall impression of Indian pharmaceutical associations and even more altogether, reduce the dependence of the private pharma associations on alone suppliers like China.
Keywords: COVID-19, outbreak, pandemic, economy, pharmaceutical, industry.
Graphical Abstract
[1]
Cucinotta, D.; Vanelli, M. WHO Declares COVID-19 a Pandemic. Acta Biomed., 2020, 91(1), 157-160.
[2]
Impact of COVID-19 on pharma supply chains., Available from: https://www.expresspharma.in/covid19-updates/impact-of-covid-on-pharma-supply-chains/
[3]
5 things pharma can learn from the coronavirus crisis, Pharma Manufacturing. 2020. Available from: https://www.pharmamanufacturing.com/articles/2020/5-things-pharma-can-learn-from-the-coronavirus-crisis/
[4]
Coronavirus pandemic threatens to cut pharmaceutical industry’s lifeline. 2020. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/coronavirus-pandemic-threatens-to -cut-pharmaceutical-industrys-lifeline/articleshow/73753415.cms?from=mdr
[6]
Aravind, M.; Manojkrishnan, C.G. COVID 19: Effect on leading pharmaceutical stocks listed with NSE. Int. J. Res. Pharm. Sci., 2020, 11(1), 31-36.
[http://dx.doi.org/10.26452/ijrps.v11iSPL1.2014]
[http://dx.doi.org/10.26452/ijrps.v11iSPL1.2014]
[7]
Andre, C. Kalil. Treating COVID-19-Off-Label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA, 2020, 323(19), 1897-1898.
[8]
Indian pharmaceuticals - a formula for success. Available from: https://www.investindia.gov.in/sector/pharmaceuticals
[9]
Indian pharmaceutical market, strong the weight of generics., Available from: https://www.pharmaworldmagazine.com/indian-pharmaceutical-market-strong-the-weight-of-generics/
[10]
Indian Pharmaceuticals Industry Report. Available from: https://www.ibef.org/industry/pharmaceutical-india.aspx
[11]
What are APIs and how they threaten India’s status of a ‘pharmacy to the world. Available from: https://theprint.in/theprint-essential/what-are-apis-and-how-they-threaten-indias-status-of-a-pharmacy-to-the-world/370941/
[12]
India’s increased dependence on Chinese APIs causing concern. Available from: https://www.thehindubusinessline.com/companies/indias-dependence-on-chinese-imports-for-api-maximum-over-last-three-years/article30051154.ece
[13]
Import of Bulk Drugs/APIs. Available from: https://pib.gov.in/PressReleseDetail.aspx?PRID=1606725
[14]
Value of Indian pharmaceutical exports from financial year. 2012. Available from: https://www.statista.com/statistics/1038136/india-value-of-pharmaceutical-exports/
[15]
Pharmaceutical Export Promotion Council of India 15th Annual Report 2018-19. Available from: https://pharmexcil.com/uploadfile/ufiles/AnnualReport05092019.pdf
[16]
A lockdown in China can cause supply chain disruptionshttps. Available from: indiaincgroup.com/a-lockdown-in-China-can-cause-supply-chain-disruptions-india-global-business/
[17]
Coronavirus: Economic impact and the road ahead. Available from: https://www.grantthornton.in/insights/articles/coronavirus-economic-impact-and-the-road-ahead/
[18]
Thacker Teena Covid-19 impact: Government panel lists essential drugs that can run out. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/covid-19-impact-government-panel-lists-essential-drugs-that-can-run-out/articleshow/74449944.cms
[19]
OEC countries profile 2017. 2017. Available from: https://www.oecd.org/regional/country-profiles.htm
[20]
Limited immediate risk from Covid-19 to India pharma sector. Available from: https://health.economictimes.indiatimes.com/news/pharma/limited-immediate-risk-from-covid-19-to-india-pharma-sector/74300251
[21]
India to boost drug ingredient output to pare China reliance. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/india-to-boost-drug-ingredient-output-to-pare-China-reliance/articleshow/75128876.cms?from=mdr
[22]
Lockdown resulting in drugs, medical devices supply disruption: Industry. 2020. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lockdown-resulting-in-drugs-medical-devices-supply-disruption-industry/articleshow/74810847.cms?from=mdr
[23]
Lockdown: Pharma, medical devices units working only at 20-30% of capacity. Available from: https://www.thehindubusinessline.com/news/lockdown-pharmaceuticals-medical-devices-production-units-working-only-20-30-per-cent-of-capacity-says-government/article31305317.ece
[24]
Bhattacharya, S.; Hossain, M.M.; Singh, A. Addressing the shortage of personal protective equipment during the COVID-19 pandemic in India-A public health perspective. AIMS Public Health, 2020, 7(2), 223-227.
[http://dx.doi.org/10.3934/publichealth.2020019] [PMID: 32617351]
[http://dx.doi.org/10.3934/publichealth.2020019] [PMID: 32617351]
[25]
COVID-19 Impact on Health Product Supply:Assessment and Recommendations. Available from: https://www.theglobalfund.org/media/9440/psm_covid-19impactonsupplychainlogistics_reort_en.pdf?u=637196033260000000
[26]
COVID-19 response for Pharma companies. Available from: https://www2.deloitte.com/in/en/pages/risk/articles/in-ra-covid-19-response-for-pharma-companies.html
[27]
COVID-19: Managing supply chain risk and disruption. Available from: https://www2.deloitte.com/global/en/pages/risk/articles/covid-19-managing-supply-chain-risk-and-disruption.html
[28]
Current status of availability of Coronavirus drugs in India. Available from: https://pib.gov.in/PressReleseDetail.aspx?PRID= 1605047
[29]
Critical Priorities for Pharma and Medtech in Response to COVID-19. Available from: https://www.bcg.com/en-in/publications/2020/coronavirus-critical-priorities-pharma-medtech-response.aspx
[30]
Annex COVID-19 Trade and trade-related measures 2020. Available from: https://www.wto.org/english/tratop_e/covid19_e/covid_measures_e.pdf
[31]
Rs 14,000 crore package to promote production of bulk drugs, medical devices. Available from: economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/rs-14000-cr-package-to-promote-production-of-bulk-drugs-medical-devices/articleshow/74751970.cms(Accessed 17April, 2020)
[32]
Covid-19 Impact: Pharma companies feel the pain as prices of key inputs shoot up. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/covid-19-impact-pharma- companies-feel-the-pain-as-prices-of-key-inputs-shoot-up/articleshow/74144044.cms?from=mdr
[33]
Coronavirus: 'No shortage of medicines, prices won't increase. Available from: https://www.businesstoday.in/sectors/pharma/coronavirus-no-shortage-of-medicines-prices-wont-increase-covid-19/story/398189.html
[34]
Exporters line up for restricted Active Pharmaceutical Ingredients licence. Available from: https://economictimes.indiatimes.com/news/economy/policy/exporters-line-up-for-restricted-active-pharmaceutical-ingredients-licence/articleshow/74642481.cms?from=mdr
[36]
Inglot, A.D. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J. Gen. Virol., 1969, 4(2), 203-214.
[http://dx.doi.org/10.1099/0022-1317-4-2-203] [PMID: 4306296]
[http://dx.doi.org/10.1099/0022-1317-4-2-203] [PMID: 4306296]
[37]
Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19). Available from: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
[38]
India’s Drugmakers Ramp Up Production Of ‘Game-Changer’ Coronavirus Drug Hydroxychloroquine. Available from: https://www.forbes.com/sites/anuraghunathan/2020/04/09/indias-drugmakers-ramp-up-production-of-game-changer-coronavirus-drug-hydroxychloroquine/#64a468fa5d5a
[39]
RAJAGOPA Divya Covid-19: Indian pharma companies want government to airlift APIs from China. 2020. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/drug- cos-want-govt-to-airlift-apis-from-China/articleshow/74956938.cms?from=mdr
[40]
Coronavirus update: India ships hydroxychloroquine tablets to 13 countries. Available from: https://www.businesstoday.in/current/world/coronavirus-update-india-ships-hydroxychloroquine-tablets-to-13-countries/story/400728.html
[41]
India to ship hydroxychloroquine tablets to 13 countries in first consignment. Available from: https://www.indiatoday.in/india/story/india-ship-hydroxychloroquine-tablets-countries-first-consignment-1665759-2020-04-11
[42]
Coronavirus outbreak: Pharma market grows 9% in March, due to panic buying. Available from: https://www.business-standard.com/article/companies/panic-buying-amid-coronavirus-lockdown-helped-pharma- market-grow-9-120040801570_1.html
[43]
ICRA downgrades Indian pharma on China lockdown. Available from: economictimes.indiatimes.com/markets/stocks/news/icra-downgrades-indian-pharma-on-China-lockdown/articleshow/74235993.cms
[44]
Covid-19 outbreak unlikely to impact credit rating of pharma companies. Available from: https://www.thehindubusinessline.com/economy/covid-19-outbreak-unlikely-to-impact-credit-rating-of-pharma- companies/article31060441.ece
[45]
Demand for ePharma Surges During COVID-19: Here’s 8 Strategies Marketers Can Adopt Right Away. Available from: https://useinsider.com/strategies-pharma-marketers-can-adopt/(Accessed 30 April, 2020)
[46]
Pharma Digitalisation: Challenges and opportunities in transforming the pharma industry. Available from: https://www.europeanpharmaceuticalreview.com/article/51733/pharma-digitalisation-challenges/(Accessed 2 May 2020)
[47]
Covid-19 epidemic will reshape patient behaviour, accelerating digitalisation of healthcare system. Available from: https://www.pharmaceutical-technology.com/comment/digital-medical-services-covid-19/
[48]
Covid lockdown: Buying from home leads to surge in e-pharmacy sales. 2020. Available from: https://health.economictimes.indiatimes.com/news/pharma/covid-lockdown-buying-from-home-leads-to-surge-in-e-pharmacy-sales/75058062
[49]
Epidemic Response to COVID-19 in Pharmaceutical and Healthcare Industries Issue 2 impact of COVID-19 on health industry and how certain sector will cope and use as it impetus for change. Available from: https://www.pwccn.com/en/healthcare/publications/epidemic-response-covid-19-issue-2.pdf
[50]
Digitization in the Pharmaceutical industry. Available from: https://www.yesbank.in/pdf/digitization_in_the_pharmaceutical_industry.pdf
[51]
Impact of AI and Digitalization on R&D in Biopharmaceutical Industry. Available from: https://www.innoplexus.com/blog/the-impact-of-digitalization-and-ai-on-rd-in-the-biopharmaceutical-industry/
[52]
Long-term Impact of COVID-19 Pandemic on Healthcare Scenario in India. Available from: https://www.expresspharma.in/guest-blogs/long-term-impact-of-covid-19-pandemic-on-healthcare-scenario-in-india/
[53]
Govt initiatives lessen manufacturing and supply chain disruptions in Indian pharma industry: GlobalData. 2020. Available from: https://www.expresspharma.in/covid19-updates/govt-initiatives-lessen-manufacturing-and-supply-chain-disruptions-in-indian-pharma-industry- globaldata/
[54]
COVID-19: A lot done, more needs to be done. Available from: andblogs.com/2020/03/covid-19-a-lot-done-more-needs-to-be-done/
[55]
COVID-19 Crisis Will Open up Opportunities for India's Pharma Industry that Must Be Seized. Available from: https://thewire.in/economy/covid-19-india-pharma-opportunities
[56]
Covid-19: Logistics, shortage of manpower major challenges for pharma industry, says Laurus Labs chief. Available from: https://www.thehindubusinessline.com/companies/covid-19-logistics-shortage-of- manpower-major-challenges-for-pharma-industry-says-laurus-labs-chief/article31403337.ece
[57]
COVID-19 impact: Labour shortage causes 50% drop in pharma production; Baddi, Daman worst hit. Available from: https://www.cnbctv18.com/healthcare/unavailability-of-workers-drags-pharmaceutical- manufacturing-to-less-than-half-5666671.htm
[58]
Challenges and prospects for clinical trials in India A regulatory perspective. Available from: https://icrier.org/pdf/Challenges-and-prospects-of- clinical-trials-in-India.pdf
[59]
Clinical trial delays become reality as Covid-19 risk spreads. Available from: https://www.evaluate.com/vantage/articles/analysis/clinical-trial-delays-become-reality-covid-19-risk-spreads
[60]
Clinical trial delays become reality as Covid-19 risk spreads. 2020. Available from: https://www.evaluate.com/vantage/articles/analysis/clinical-trial-delays-become-reality-covid-19-risk-spreads
[61]
A Covid-19 Action Plan for Pharma Executives. Available from: https://www.bain.com/insights/a-covid-19-action-plan-for-pharma/
[62]
The impact of the Covid-19 pandemic on clinical trials. Available from: https://www.clinicaltrialsarena.com/comment/covid-19-pandemic-clinical-trials/
[63]
India’s pharma industry see opportunity amidst threats in the COVID-19 crisis. Available from: https://www.theweek.in/news/biz-tech/2020/03/23/indias-pharma-industry-see-opportunity-amidst-threats-in-the-covid-19-crisis.html
[64]
Covid-19 outbreak could be Indian pharma’s big opportunity in Africa. Available from: https://qz.com/india/1830849/coronavirus-could-be-indian-pharmas-big-opportunity-in-africa/
[65]
Why India depends heavily on China for drug raw materials? Available from: https://www.ha-asia.com/why-india-still-depends-on-apis-imported-from-China/
[66]
Coronavirus calls for pharma rethink. Available from: https://www.financialexpress.com/opinion/coronavirus-calls-for-pharma-rethink/1905160/
[67]
What are APIs and how they threaten India’s status of a ‘pharmacy to the world. Available from: https://theprint.in/theprint-essential/what-are-apis-and-how-they-threaten-indias-status-of-a-pharmacy-to-the-world/370941/
[68]
Manufacturing In India vs. China. Available from: https://www.intouch-quality.com/blog/manufacturing-in-india-vs-China
[69]
Unforeseen Chinese API problems opportunity for Indian companies. Available from: http://content.icicidirect.com/mailimages/ChineseAPI.htm
[70]
Manufacturing, value added (% of GDP) of different countries. Available from: https://data.worldbank.org/indicator/NV.IND.MANF.ZS
[71]
The Indian pharmaceutical industry –the way forward. Available from: https://www.ipa-india.org/static-files/pdf/publications/position-papers/2019/ipa-way-forward.pdf
[72]
PIB Delhi. Cabinet approves Promotion of domestic manufacturing of critical Key Starting Materials/Drug Intermediates and Active Pharmaceutical Ingredients in the country. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1607483
[73]
COVID-19 Lesson: India Earmarks $1.3bn To Reduce Dependence on China. Available from: https://pink.pharmaintelligence.informa.com/PS141939/COVID19-Lesson-India-Earmarks-13bn-To-Reduce-Dependence-On-China
[74]
Indian pharmaceutical industry is expected to grow USD 130 billion by 2030: Invest India. 2020. Available from: https://newsvibesofindia.com/indian-pharmaceutical-industry-is-expected-to-grow-usd-130-billion-by-2030-invest-india/
[75]
Lythgoe, M.P.; Middleton, P. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends Pharmacol. Sci., 2020, 41(6), 363-382.
[http://dx.doi.org/10.1016/j.tips.2020.03.006] [PMID: 32291112]
[http://dx.doi.org/10.1016/j.tips.2020.03.006] [PMID: 32291112]
[76]
India’s Drug Controller Permits Clinical Trial of Convalescent Plasma In Covid-19 Patients. 2020. Available from: https://www.bloombergquint.com/coronavirus-outbreak/drug-controller-general-permits-clinical- trial-of-convalescent-plasma-in-covid-19-patients
[77]
Thorlund, K.; Drone, L.; Park, J.; Hsu, G.; Forrest, J.I.; Mills, E.J. A real-time dashboard of clinical trials for COVID-19 Lancet. Digit. Health, 2020.
[http://dx.doi.org/10.1016/S2589-7500(20)30086-8]
[http://dx.doi.org/10.1016/S2589-7500(20)30086-8]
[78]
COVID-19 Treatment and Vaccines Tracker. Available from: https://milkeninstitute.org/covid-19-tracker
[79]
These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand Available from: https://www.marketwatch.com/story/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06
[82]
Covid-19 shows why we need a healthcare reboot for India. Available from: www.livemint.com/politics/policy/will-covid-19-prompt-health-reboot-11585497828527.html
[83]
Ramping up the supply chain post COVID-19. 2020. Available from: https://home.kpmg/in/en/home/insights/2020/05/ramping-up-the-supply-chain- post-covid-19.html.
[84]
India wants to become a very significant player in the global supply chain of pharmaceuticals: Dr Sanjit Singh Lamba. Available from: https://health.economictimes.indiatimes.com/news/pharma/india-wants-to-become-a-very-significant-player-in-the-global-supply-chain-of-pharmaceuticals-dr-sanjit-singh-lamba/70458521
[85]
How to make India ready for future coronavirus-like crises. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/armed-with-solid-bio-data/articleshow/74737523.cms?from=mdr
Related Journals
Current Medicinal Chemistry
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current HIV Research
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
An Epidemiological Update on COVID -19
Frontiers in Clinical Drug Research – Anti Allergy Agents
Frontiers in Clinical Drug Research: Anti-Infectives
Article Metrics
31
1